March 7, 2019
Targeted Radiation Therapy Yields High Response Rates in Metastatic Prostate Cancer BookmarkEmma Shtivelman, PhD
“The targeted radiation therapy Lutetium-177 PSMA-617 produced high response rates among men with prostate-specific membrane antigen-positive metastatic, castration-resistant prostate cancer, according to results of a single-arm, phase 2 trial scheduled for presentation at Genitourinary Cancers Symposium.
“The treatment also appeared well-tolerated among these men, whose disease had progressed after multiple standard therapies.”
Go to full article published by Healio on Feb 14, 2019.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.